Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 6:01 pm Sale | 2024-09-30 | 13G | Jasper Therapeutics, Inc. JSPR | Avidity Partners Management LP | 0 0.000% | -760,000 (Position Closed) | Filing History |
| 2024-11-14 3:32 pm Purchase | 2024-09-30 | 13G | Jasper Therapeutics, Inc. JSPR | Soleus Private Equity Fund III L.P. | 1,343,665 9.000% | 1,343,665 (New Position) | Filing History |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | Jasper Therapeutics, Inc. JSPR | BlackRock Inc. BLK | 800,028 5.300% | 0 (Unchanged) | Filing History |
| 2024-11-04 12:05 pm Purchase | 2024-09-30 | 13G | Jasper Therapeutics, Inc. JSPR | SPHERA FUNDS MANAGEMENT LTD. | 189,270 1.250% | 189,270 (New Position) | Filing History |
| 2024-10-22 6:06 pm Purchase | 2024-09-30 | 13G | Jasper Therapeutics, Inc. JSPR | BlackRock Inc. BLK | 800,028 5.300% | 800,028 (New Position) | Filing History |
| 2024-03-27 4:26 pm Purchase | 2024-03-18 | 13G | Jasper Therapeutics, Inc. JSPR | Avidity Partners Management LP | 760,000 5.100% | 760,000 (New Position) | Filing History |
| 2024-02-14 6:18 pm Sale | 2023-12-31 | 13G | Jasper Therapeutics, Inc. JSPR | CITADEL ADVISORS LLC | 230,620 0.200% | -142,287 (-38.16%) | Filing History |
| 2024-02-14 4:18 pm Purchase | 2023-12-31 | 13G | Jasper Therapeutics, Inc. JSPR | Qiming U.S. Healthcare Fund II L.P. | 928,964 6.200% | 928,964 (New Position) | Filing History |
| 2024-02-14 09:41 am Sale | 2023-12-31 | 13G | Jasper Therapeutics, Inc. JSPR | BIOTECHNOLOGY VALUE FUND L P | 0 0.000% | -990,000 (Position Closed) | Filing History |
| 2024-02-12 6:00 pm Purchase | 2024-02-08 | 13D | Jasper Therapeutics, Inc. JSPR | Carlyle Group Inc. CG | 1,066,189 7.100% | 190,000 (+21.68%) | Filing History |
| 2024-02-09 8:36 pm Purchase | 2024-02-08 | 13D | Jasper Therapeutics, Inc. JSPR | Velan Capital Investment Management LP | 1,471,903 9.800% | 1,471,903 (New Position) | Filing History |
| 2024-02-05 09:15 am Purchase | 2023-12-31 | 13G | Jasper Therapeutics, Inc. JSPR | SPHERA FUNDS MANAGEMENT LTD. | 7,130,625 6.390% | 6,561,912 (+1153.82%) | Filing History |
| 2024-02-02 09:50 am Purchase | 2023-12-31 | 13G | Jasper Therapeutics, Inc. JSPR | Soleus Capital Master Fund, L.P. | 987,096 8.800% | 987,096 (New Position) | Filing History |
| 2023-10-10 11:15 am Purchase | 2023-09-27 | 13G | Jasper Therapeutics, Inc. JSPR | SPHERA FUNDS MANAGEMENT LTD. | 568,713 5.130% | 568,713 (New Position) | Filing History |
| 2023-02-27 4:05 pm Unchanged | 2023-02-16 | 13D | Jasper Therapeutics, Inc. JSPR | Velan Capital Investment Management LP | 1,121,904 10.200% | 0 (Unchanged) | Filing History |
| 2023-02-14 08:26 am Purchase | 2022-12-31 | 13G | Jasper Therapeutics, Inc. JSPR | CITADEL ADVISORS LLC | 372,907 9.900% | 4,787 (+1.30%) | Filing History |
| 2023-02-13 4:49 pm Unchanged | 2022-12-31 | 13G | Jasper Therapeutics, Inc. JSPR | ROCHE FINANCE LTD | 462,461 4.200% | 0 (Unchanged) | Filing History |
| 2023-02-10 4:18 pm Sale | 2023-01-31 | 13G | Jasper Therapeutics, Inc. JSPR | AMGEN INC AMGN | 100,993 0.900% | -169,007 (-62.60%) | Filing History |
| 2023-02-06 4:43 pm Purchase | 2023-01-25 | 13G | Jasper Therapeutics, Inc. JSPR | BIOTECHNOLOGY VALUE FUND L P | 990,000 9.100% | 990,000 (New Position) | Filing History |
| 2023-01-31 4:15 pm Purchase | 2023-01-27 | 13D | Jasper Therapeutics, Inc. JSPR | Carlyle Group Inc. CG | 876,189 8.000% | 313,333 (+55.67%) | Filing History |